Prestige Consumer Healthcare Future Growth
Future criteria checks 3/6
Prestige Consumer Healthcare is forecast to grow earnings and revenue by 36% and 2.1% per annum respectively. EPS is expected to grow by 36.2% per annum. Return on equity is forecast to be 11.4% in 3 years.
Key information
36.0%
Earnings growth rate
36.2%
EPS growth rate
Pharmaceuticals earnings growth | 20.0% |
Revenue growth rate | 2.1% |
Future return on equity | 11.4% |
Analyst coverage | Good |
Last updated | 09 Jan 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2026 | 1,187 | 228 | 270 | 268 | 2 |
3/31/2025 | 1,162 | 230 | 273 | 277 | 7 |
3/31/2024 | 1,136 | 216 | 264 | 259 | 7 |
9/30/2023 | 1,127 | -82 | 216 | 224 | N/A |
6/30/2023 | 1,130 | -84 | 211 | 220 | N/A |
3/31/2023 | 1,128 | -82 | 222 | 230 | N/A |
12/31/2022 | 1,109 | 210 | 225 | 234 | N/A |
9/30/2022 | 1,108 | 209 | 236 | 245 | N/A |
6/30/2022 | 1,095 | 203 | 240 | 249 | N/A |
3/31/2022 | 1,087 | 205 | 250 | 260 | N/A |
12/31/2021 | 1,058 | 189 | 245 | 256 | N/A |
9/30/2021 | 1,022 | 179 | 224 | 239 | N/A |
6/30/2021 | 983 | 179 | 209 | 230 | N/A |
3/31/2021 | 943 | 165 | 213 | 236 | N/A |
12/31/2020 | 957 | 166 | 207 | 233 | N/A |
9/30/2020 | 960 | 163 | 218 | 241 | N/A |
6/30/2020 | 960 | 152 | 222 | 240 | N/A |
3/31/2020 | 963 | 142 | 203 | 217 | N/A |
12/31/2019 | 953 | -34 | 199 | 212 | N/A |
9/30/2019 | 953 | -34 | 186 | 197 | N/A |
6/30/2019 | 954 | -36 | 176 | 186 | N/A |
3/31/2019 | 976 | -36 | 179 | 189 | N/A |
12/31/2018 | 991 | 64 | 183 | 193 | N/A |
9/30/2018 | 1,020 | 340 | 184 | 197 | N/A |
6/30/2018 | 1,039 | 340 | 199 | 212 | N/A |
3/31/2018 | 1,041 | 340 | 198 | 210 | N/A |
12/31/2017 | 1,026 | 390 | 152 | 163 | N/A |
9/30/2017 | 972 | 107 | 97 | 156 | N/A |
6/30/2017 | 929 | 109 | N/A | 151 | N/A |
3/31/2017 | 882 | 69 | N/A | 149 | N/A |
12/31/2016 | 849 | 72 | N/A | 179 | N/A |
9/30/2016 | 833 | 69 | N/A | 185 | N/A |
6/30/2016 | 824 | 68 | N/A | 182 | N/A |
3/31/2016 | 806 | 100 | N/A | 176 | N/A |
12/31/2015 | 788 | 110 | N/A | 189 | N/A |
9/30/2015 | 786 | 103 | N/A | 190 | N/A |
6/30/2015 | 761 | 88 | N/A | 170 | N/A |
3/31/2015 | 715 | 78 | N/A | 156 | N/A |
12/31/2014 | 668 | 70 | N/A | 135 | N/A |
9/30/2014 | 615 | 52 | N/A | 113 | N/A |
6/30/2014 | 601 | 69 | N/A | 118 | N/A |
3/31/2014 | 597 | 73 | N/A | 112 | N/A |
12/31/2013 | 609 | 76 | N/A | 118 | N/A |
9/30/2013 | 624 | 85 | N/A | 133 | N/A |
6/30/2013 | 619 | 72 | N/A | 146 | N/A |
3/31/2013 | 620 | 66 | N/A | 138 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: P2BH34 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (9.7%).
Earnings vs Market: P2BH34 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: P2BH34 is expected to become profitable in the next 3 years.
Revenue vs Market: P2BH34's revenue (2.1% per year) is forecast to grow slower than the BR market (6.4% per year).
High Growth Revenue: P2BH34's revenue (2.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: P2BH34's Return on Equity is forecast to be low in 3 years time (11.4%).